Pharmaceutical Companies Raise Health Service Sponsorship to €58m
Pharmaceutical companies spent €58.5m sponsoring doctors, patients organisations and healthcare providers last year, the Volkskrant said on Thursday.
This is a rise of 13% on 2015, the paper said, quoting figures from the Transparantieregister Zorg, set up five years ago to provide details about healthcare sponsorship.
Most of the increase is due to extra spending on care institutions and doctors. Payment to patients organisations fell by €500,000 to €1.7m. Less money also went to pay doctors to speak at conferences, a trend which first began in Britain with GlaxoSmithKline.
Sponsoring by pharmaceutical companies is controversial because it can give rise to conflicts of interest. ‘Companies are not paying €58m in order to get nothing back. They are not philanthropists,’ said Ruud Coolen van Brakel of the IVM institute which investigates prescription patterns.
‘The sponsor cash paid to patients organisations is recouped in the price of medicines,’ he said. ‘No-one asks if we all benefit from this.’
2026-07-30
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
VIV Health & Nutrition Asia 2026 Brings Together Innovation and Business Across the Animal Feed and Health Industry
-
Two Types Of Progesterone Only Pill That Commonly Used
-
Pharmaceutical and Health Industry Special Study - The Arrival of New Opportunities
-
Four Foods that can Protect Your Heart Health
-
Selling Expired Food, Losing Money And Being Fined
-
Blood Pressure Control in Elderly Patients with Hypertension
-
The Valve Track Has Multiple Layouts, and the R&D Innovation Heat is Rising
-
Brief Intriduction of the Free Radicals in Human Body
-
CPHI CHINA 2021
-
Hi & Fi Asia-China Expo 2020
Recommend Reading
-
Aekyung Chemical Plans to Sell Its Ningbo Subsidiary
-
Sika in China Under Pressure: The Structural Alarm Behind the 1,500-Job Cut
-
Covestro Q2 Sales Down 8.4 Percent EBITDA Drops to €270 Million Outlook Cut Amid Tariff Shock and Price Squeeze
-
PPG Q2 Net Sales Reach $4.2 Billion Net Profit Down 9 Percent as Organic Growth Offsets Sector Headwinds
-
Shenma Spends 952 Million Yuan to Raise Stake in Nylon Chemical to 72 Percent Amid Profit Pressure
-
Supply Reduction Leads to Steady Increase in Cyclohexanone Prices in Shandong, China
-
This Week's Styrene Market Fluctuates and Declines (3.30-4.3)
-
This week, the caustic soda price was weak (10.27-10.30) in China
-
This week, China's acetone market continues to weaken
-
MTBE Market Trends: First Rise, Then Fall